Federal criminal charges have been filed after an asbestos demolition company’s actions exposed workers and the public to the risk of mesothelioma. The 24-count indictment filed by the U.S. Attorney’s Office accuses Carl Fioravanti, president of Alliance Environmental Control, Inc., of making false statements during the demolition of the former Lakes Behavioral Hospital in Waukegan,
Category: Uncategorized
40.6% of all EU Occupational Cancer Victims Have Mesothelioma
A report published by the European Union’s statistical office demonstrates that mesothelioma accounted for 16,469 of the 40,538 occupational cancer cases officially recognized in the European Union between 2013 and 2023. The report issued by Eurostat shows that despite steps taken to minimize asbestos exposure, the rare disease represents 40.6 percent of all diagnosed work-related
Mesothelioma Incidence Rose from 1999 to 2011, Then Declined Through 2020
A group of international researchers has published a noteworthy article concluding that the number of U.S. mesothelioma cases significantly increased from 1999 through 2011, then gradually declined through 2020. The scientists noted the higher incidence of the asbestos-related disease among individuals aged 75 years and older, men, and White populations. The group concludes that enhanced
Mesothelioma Incidence Rose from 1999 to 2011, Then Declined Through 2020
A group of international researchers has published a noteworthy article concluding that the number of U.S. mesothelioma cases significantly increased from 1999 through 2011, then gradually declined through 2020. The scientists noted the higher incidence of the asbestos-related disease among individuals aged 75 years and older, men, and White populations. The group concludes that enhanced
Family Can Continue Mesothelioma Claim Against Turbine Manufacturer
The family of mesothelioma victim Michael P. Dandry Jr. won an early legal round in its attempt to hold turbine manufacturer Paramount Global responsible for their loved one’s death. The company had filed a motion to have the occupational exposure case against it dismissed, but a U.S. District Court Judge ruled that a reasonable jury
Mesothelioma Researcher Defends Article Against Johnson & Johnson Libel Claims
Respected mesothelioma researcher Dr. Jacqueline Moline was in court last week, defending herself against claims of trade libel lodged by Johnson & Johnson’s bankrupt talc subsidiary Pecos River Talc LLC. The company’s previous claim against her had been dismissed based on First Amendment protections, but its attorneys asserted they’d found new information and refiled its
Researchers Advance Mesothelioma Treatments Using Patient Fluid and Tissue Samples
Researchers in China are creating miniaturized versions of mesothelioma tumors to create personalized treatment models for this rare and aggressive cancer. Using malignant ascites, pleural effusions, fine-needle biopsies, and surgical tissues to create patient-derived organoids (PDOs), they hope to improve the poor outcomes and therapy resistance typical of the disease.
Slow Enrollment Frustrates Mesothelioma Trial of Imfinzi
According to a report presented at the 2025 ESMO Congress, mesothelioma patients treated with first-line Imfinzi (durvalumab) plus chemotherapy achieved a median overall survival of 21 months compared to 18 months with chemotherapy alone in the phase 3 DREAM3R study. However, slow patient enrollment and shifting standards of treatment complicated the study’s protocol, leading to
Could Discovery Regarding COVID-19 mRNA Vaccines Help Mesothelioma Patients?
Groundbreaking research published in the journal Nature has given rise to hope that mesothelioma patients could experience improved responses to immunotherapy treatment when combined with COVID-19 mRNA vaccines. A collaborative group of scientists from some of the world’s best cancer centers has found that SARS-CoV-2 vaccines sensitize immunologically “cold” tumors to immunotherapy and trigger powerful
Preclinical Study Shows Selective A2B Receptor Inhibitor Enhances Mesothelioma Immunotherapy
Researchers from Cyncado Therapeutics say that TT-4 monotherapy outperforms anti-PD-1 checkpoint inhibitors in treating mesothelioma, and that combining the two improves anti-tumor activity and increased T-cell infiltration even more. The group will be presenting details of its research at the upcoming AACR-NCI-EORTC International Conference to be held in Boston, Massachusetts, this coming weekend.